Inhibitex Expects Neonatal Anti-Infective Veronate To Gain Broad Formulary Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
Expected American Academy of Pediatrics endorsement will drive utilization, CEO Johnston says. The orphan S. aureus and Candida prophylactic, currently in Phase III, has broader pathogen coverage than potential competitor Nabi’s Altastaph, he maintains. MedImmune’s Synagis will pave the way for acceptance of the antibody, he says.
You may also be interested in...
Nabi Seeking StaphVax Indication For All At-Risk Groups; BLA Filing Planned By End Of 2005
Company announces initiation of Phase IIb immunogenicity trials for prevention of S. aureus infection in cardiovascular and orthopedic surgery patients July 22. Trials will complement ongoing confirmatory Phase III trial in end-stage renal disease patients.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.
Pozen’s Migraine Agent To Be Focus Of FDA Advisory Committee Review
Naproxen/metoclopramide combination is expected to be reviewed by the Peripheral & Central Nervous System Drugs Advisory Committee May 4. Potential risk of tardive dyskinesia is expected to be discussed. FDA deemed MT-100 “not approvable” earlier this year.